Amgen Lung Cancer Drug Approved by FDA

The U.S. Food and Drug Administration gave accelerated approval to Lumakras, a drug from Amgen Inc. for adult patients with non-small cell lung cancer.

LTC Sells Three Wisconsin Properties for $35 Million

Real estate investment trust LTC Properties, which specializes in health care property and senior housing investments, has announced a $35 million sale of three assisted living properties in Wisconsin.

Amgen Signs $1.25 Billion Deal to Develop Skin Treatment

Amgen Inc. on Tuesday announced a $1.25 billion deal with Kyowa Kirin Co. Ltd. to jointly develop and commercialize Kyowa’s treatment for atopic dermatitis, KHK4083.

Tease photo

Providence St. Joseph Hospital Chief Executive Steps Down

Kelly Linden stepped down as chief executive of Providence St. Joseph Medical Center in Burbank effective May 14.

Amgen Keeps Patent Protection for Enbrel With Supreme Court Decision

The U.S. Supreme Court declined to hear Novartis AG’s appeal of a lower court’s decision on Monday, allowing Amgen Inc. to keep its patent protection for the rheumatoid arthritis drug Enbrel until 2029.

Second Sight Shares Climb as Orion Study Shows Improved Vision

Second Sight Medical Products Inc. closed up more than 27 percent after announcing the results of a two-year study of its Orion visual prosthesis.

Amgen Stomach Cancer Drug Earns FDA Breakthrough Status

A stomach cancer drug in development by Amgen Inc. has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration.

Medtronic Launches Large-Capacity Insulin Pump Technology

Medtronic has launched its diabetes extended infusion set in some European countries.

Memory Care Facility Opens in Thousand Oaks

Assisted living facility chain Silverado Senior Living has opened its newest memory care center in Thousand Oaks, its first location in Ventura County.

Tease photo

Second Sight’s Argus II System Receives FDA Approval

Second Sight Medical Products announced its Argus IIs Retinal Prosthesis System was approved by the U.S. Food and Drug Administration.

Amgen to Acquire Five Prime Therapeutics for $1.9 Billion

Amgen Inc. plans to acquire Bay Area biotech company Five Prime Therapeutics for $1.9 billion in cash, or $38 per share.

Lancaster, Kaiser Permanente Partner to Open Mass Vaccination Site

The City of Lancaster, in partnership with Kaiser Permanente, will open a mass vaccination site at the Antelope Valley Fairgrounds on March 8.

MannKind Convertible Notes to Raise $150 Million as Shares Fall 30 Percent

MannKind Corp. on Monday announced it intends to offer a private placement of convertible senior notes worth $150 million.

Preview: A Second Sight Buyout Strategy

Companies combine technology for visual prosthetics.

Afrezza Quarterly Sales Increase, New Therapies on Horizon at MannKind

MannKind Corp. touted increased sales for its flagship drug Afrezza during its fourth quarter earnings report, while pointing out its new direction toward therapies for lung and endocrine diseases.